Press Releases September 8, 2026 04:05 PM

Journey Medical Corporation to Participate in September 2026 Investor Conferences

Journey Medical Corporation to Present at September 2026 Investor Conferences in New York City

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
DERM

Journey Medical Corporation, a Nasdaq-listed pharmaceutical company specializing in FDA-approved dermatology prescription products, announced CEO Claude Maraoui's participation in two investor conferences in September 2026. The company will present at the Lake Street Capital Markets 10th Annual Best Ideas Growth Conference and the H.C. Wainwright 28th Annual Global Investment Conference. A webcast of the H.C. Wainwright presentation will be available on the company website for 30 days.

Journey Medical Corporation to Participate in September 2026 Investor Conferences
DERM
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Journey Medical focuses on developing, selling, and marketing FDA-approved dermatological prescription products.
  • CEO Claude Maraoui will participate in two major investor conferences in New York City in September 2026.
  • A webcast of the company's presentation at the H.C. Wainwright conference will be accessible via their website for 30 days post-event.

SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2026 investor conferences.

Details of the events are as follows:

Lake Street Capital Markets 10th Annual Best Ideas Growth (BIG10) Conference
Date: Thursday, September 10, 2026
Location: New York City
Format: 1x1 Meetings

H.C. Wainwright 28th Annual Global Investment Conference
Date and Time: Monday, September 14, 2026, at 10:00 a.m. ET
Location: New York City
Format: Presentation and 1x1 Meetings

A webcast of the Company’s presentation at H.C. Wainwright will be available on the News and Events page of the Investors section of Journey Medical’s website, www.journeymedicalcorp.com, for approximately 30 days after the meeting.

About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets nine branded FDA-approved prescription drugs that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and the company files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com.

Company Contact:
Jaclyn Jaffe
Journey Medical Corporation
(781) 652-4500
[email protected]

Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
[email protected]


Risks

  • No new product announcements or financial updates were provided, which may limit immediate investor reaction.
  • Market dynamics in pharmaceutical and healthcare sectors remain competitive and can affect company growth.
  • Participation in investor conferences does not guarantee positive stock movement without substantive news or performance updates.

More from Press Releases

Prestige Consumer Healthcare Inc. to Participate in Barclays Global Consumer Conference Sep 8, 2026 Eldorado Gold Announces First Copper-Gold Concentrate at Skouries Sep 8, 2026 Acco Group Holdings Limited Announces the Launch of Licensed Corporate Service Operations in Singapore, Expanding its Regional Corporate Services Footprint Sep 8, 2026 Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update Sep 8, 2026 Elevra Lithium Announces NAL Expansion Pre-Feasibility Study Sep 8, 2026